Omberacetam (Noopept)
Synthetic Dipeptide | Cognitive Enhancement Nootropic
Omberacetam (also known as Noopept or GVS-111) is a synthetic nootropic dipeptide (N-phenylacetyl-L-prolylglycine ethyl ester) developed in Russia in 1996 for its potent cognitive-enhancing and neuroprotective properties. While structurally distinct from racetams, it's considered part of the nootropic family and functions as a prodrug that converts to the active metabolite cycloprolylglycine (CPG). Research indicates it may enhance memory, learning, and neuroplasticity through BDNF/NGF upregulation and glutamatergic modulation at doses 1000x lower than piracetam.
Daily dose
10-30mg
Frequency
1-3 times daily
Cycle length
4-8 weeks on, 2-4 weeks off
Storage
Room temperature, protect from moisture
Key benefits
Primary administration route, rapid oral bioavailability, convenient dosing, well-studied in clinical trials, peak absorption within 7 minutes
How it works
Rapidly absorbed orally and converted to active metabolite cycloprolylglycine (CPG) which modulates AMPA/NMDA glutamate receptors and enhances cholinergic neurotransmission
Dosage protocols
Goal
Cognitive enhancement (beginner)
Dose
10mg · 1-2 times daily
Route
Oral (sublingual or swallowed)
Goal
Standard cognitive support
Dose
10-20mg · 2-3 times daily
Route
Oral, taken with or without food
Goal
Intensive cognitive enhancement
Dose
20-30mg · 2-3 times daily
Route
Oral, cycled 4-8 weeks
Goal
Cognitive recovery support
Dose
20mg · Twice daily
Route
Oral (as studied in clinical trials)
Research indications
cognitive
neuroprotective
neuroplasticity
Administration
Interactions
Safety notes
Start with 10mg once daily to assess individual response before increasing dose
Always pair with a choline source (Alpha-GPC or CDP-Choline) to prevent headaches
Avoid evening dosing as cognitive stimulation may interfere with sleep
Do not combine with other strong cholinergic or glutamatergic compounds without caution
Not recommended for pregnant or breastfeeding women due to lack of safety data
Individuals with liver conditions should consult healthcare provider before use
Research studies
Neuroprotection in Alzheimer's Model (2015)
Cellular | Human cortical neurons | β-amyloid/tau phosphorylation model | Multiple concentrations
Omberacetam demonstrated significant neuroprotective effects against Alzheimer's disease-related pathology, attenuating apoptosis and reducing tau hyperphosphorylation in human neuronal cells exposed to amyloid-beta toxicity.
Neurotrophic Factor Expression (2009)
Animal | Rat | 0.5mg/kg IP | Single dose | Hippocampal analysis
Acute administration elevated BDNF mRNA levels by up to 1.4-fold and NGF mRNA by 1.3-fold in hippocampus within 3 hours post-injection, demonstrating rapid neurotrophic activity supporting neuroplasticity.
Human Cognitive Enhancement Trial (2008)
Human | 53 patients | 20mg daily vs Piracetam 1200mg | 56 days | Cerebrovascular/post-traumatic conditions
Patients with cognitive impairment from vascular cerebral damage or post-traumatic injury showed universal improvement on measured parameters. MMSE scores increased from 26 to 29 in the Omberacetam group with 1.8-fold fewer side effects compared to piracetam.
Spatial Memory Restoration Study (2007)
Animal | Mouse Alzheimer's model | 0.01mg/kg daily | 21 days
Chronic administration restored spatial memory and increased serum antibody levels to amyloid-beta oligomers in mice with Alzheimer's disease-like pathology, demonstrating potential disease-modifying effects.